Overview

Natesto Testosterone Nasal Gel for Hypogonadal Men

Status:
Recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
To determine if testosterone deficient men who are using daily Tadalafil (a phosphodiesterase-5 Inhibitor), will have a significant improvement in erectile function and satisfaction with erectile dysfunction treatment when using on-demand Testosterone Nasal Gel (TNG) prior to sexual activity compared to placebo.
Phase:
Phase 4
Details
Lead Sponsor:
University of Utah
Collaborator:
Acerus Pharmaceuticals Corporation
Treatments:
Methyltestosterone
Testosterone
Testosterone 17 beta-cypionate
Testosterone enanthate
Testosterone undecanoate